Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost.

However, a numerical increasing trend in ZBP was documented in LD-ITI but without significant difference (28.9% vs 18.4%; P = .091) as shown in Figure C. 3.3 Comparison of QoL assessment between EMI group and ITI group 3.3.1 CHO-KLAT scores The parent proxy-reported and children self-reported CHO-KLAT scores after EMI or ITI treatment were shown in Figure D.

also in 13 other papers